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1. Introduction 
Cancer now is well described as a genetically defective disease that causes the overgrowth 
of particular cells. Cancer is phenotypically related to multiple sequential gene mutation 
and amplification, genetic translocalization, preservation of telomeres and loss of tumor 
suppressor gene that lead to immortal cell (Sinkovics & Horvath, 2000). In this regard, 
gliomas are particularly defined as pathological tumors that display histological, 
immunohistological and ultrastructural evidence of glial differentiation (Maher  et al., 2001).  
Amongst gliomas, glioblastoma multiform (GBM) is one of the most killer cancer and 
maintains its prevalence despite current millennium intelligent treatment.   
Taking advantage of the genetic defects that fuel cancer growth, targeted therapy using 
viruses to kill mutated or defective-gene cancer cells was investigated. Viruses with 
oncolytic properties and limited side effects to human were used as miniature biological 
machine to reach the targeted cancer cells. In this progressing treatment modality, the 
viruses were specifically studied to reach the targeted cancer without interfering the normal 
cells, directly inducing cancer cell death or activating the body immune system to infiltrate 
and mediate the destruction of tumor mass.  
Basically, the targeted therapy using virus can be classified into two classes which are 
replication-defective virus that is mainly used as a vehicle for gene therapy by means as a 
vector for suicide gene delivery and also a replication-competent virus (Biederer et al., 2002). 
Some of the replication-competent viruses that have been studied, focused on its natural-
selective oncotropic to invade cancerous cells and the others were armed with a genetically 
engineer technique to activate cell death promoter genes. 
As the malignant gliomas are amongst the few rapidly proliferating ones in central nervous 
system, it is becoming an interesting subject for the study of selective-amplifications virus 
(Aghi et al., 2006).  
In the beginning of this century, it was noted that a patient with cervical carcinoma 
experienced significant tumor regression after rabies vaccination. In addition, there were 
reports of remissions of Burkitt’s and Hodgkin’s lymphomas following natural infection 
with measles virus. In the 1950s, human trials with several potentially oncolytic viruses 
were initiated (Evert and Henk G., 2005). 
Preclinical studies of oncolytic viruses in gliomas emerged in 1990’s where the first 
attenuated Herpes Simplex Virus and Adenovirus were used followed by oncolytic 
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Reovirus. To date, four viruses have completed the clinical trials. The viruses are Herpes 
Simplex Virus (HSV-1, HSV-1716 & HSV-G207), Newcastle Disease Virus (MTH-68/H, 
NDV-Huj), Adenovirus (Onyx-015) and Reovirus. As the general outcomes of phase 1 trials, 
the viruses were declared as safe to be injected directly to the brain and no maximum 
tolerate dose (MTD) were reached. Some anti-glioma activities were also found. Amongst 
these, NDV showed the most promising benefits with 6 patients showed tumor regression 
and 3 patients have long term survival (Franz et al., 2010). 
In this chapter, taking an example of Newcastle disease virus, we focus on the advantages of 
virotherapy, targeted pathway in oncolysis mechanism, methodology for virus with 
oncolytic properties study, and development of tumor model for glioma in a mouse model.   
2. Oncolytic virus therapy 
Oncolytic virus refer to the virus that kills tumor cells selectively  without harming the 
normal surrounding tissue (Biederer et al., 2002; Franz et al., 2010). As a mode of therapy, 
oncolytic virus is used to “self-recognize” and infect the mutated cancerous cells which 
replicates within the infected cells followed by release of new virion that simultaneously 
amplifies the input dose.  New virions later spreads and infect the adjacent cancerous cells. 
Consequently, infected cells often undergo pathological programmed cell death which  also 
known as apoptosis.  
This application modality reflects the application of viruses with replication-competent and 
inheriting the natural selective capability to the cancerous cells. Most studied natural 
oncotropic viruses are the RNA viruses such as paramyxovirus family including newcastle 
disease virus (NDV), reovirus, and vesicular stomatitis virus. 
Moreover, some viruses were also enhanced with genetic modification by insertion or 
deletion of therapeutic transgenes respectively (Marianne et al., 2010). Virus can be made 
tumor selective by modification of the cellular tropism at the level of viral replication in a 
way that it becomes dependent on specific characteristics of tumor cells for viral replication. 
This can be achieved by deleting viral genes that are critical for viral replication in healthy 
cells but are dispensable upon infection of neoplastic cells. Modification of the cellular 
tropism at the level of cell recognition and binding by altering the viral coat for tumor-
selective binding and uptake may also be performed (Evert and Henk G., 2005) 
For example, the most common immune-modulatory protein inserted into the oncolytic 
viruses is the granulocyte-macrophages colony-stimulating factor (GM-CSF) that has been 
inserted into the adenovirus, herpes simplex virus and vaccinia virus in order to stimulate 
an inflammatory response within the tumor microenvironment (Marianne et al., 2010) and 
promoting cell death. 
Research of the oncolytic virus also been studied along with current conventional treatments 
and the virotherapeutics have demonstrated synergy with the approved chemotherapeutics 
and radiotherapy (Liu et al, 2007). 
In past decade, the oncolytic viruses have been tested on various human cancer cells in-vitro 
and animal model with very promising benefits (Schirrmacher and Fournier, 2009). Some of 
the oncolytic virus been studied and reported in phase 1 against glioma are the herpes 
simplex virus (HSV), adenovirus, reovirus, and NDV, while the measles virus, vaccinia 
virus, myxoma virus, polio virus, and vesicular stomatitis virus were at the preclinical level. 
(Parker et al., 2009) 
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For NDV, the strain been studied on glioma are the MTH/68H, NDV-HUJ,OV-001, 73-T and 
V4UPM. The V4UPM is the avirulent strain of ND virus that has been used as a 
thermostable feed pellet vaccine for poultry. It is been tested to poses excellent oncolytic 
activity against glioma cell lines. (Zulkifli et al., 2009) 
 
 
Fig. 1. An example of apoptotic glioma cells infected with newcastle disase virus (40x) 
To date, there are 119 patients recruited for clinical trials. HSV (strain G207 & HS-1716), 
adenovirus (strain ONYX-015), reovirus and NDV (strain NDV-HUJ) have completed the 
phase 1 clinical trials. NDV strain MTH-68/H reported in several case reports against 
gliomas. (Franz et al., 2010) .   
In the clinical practice, China is reported to be the first country that has approved the 
oncolytic virus application in 2006. The virus is the genetically modified adenovirus strain 
H101 that has been reported to enhance anticancer rate response compared to chemotherapy 
alone. 
3. Advantages and disadvantages of viral therapy 
In current conventional treatments, gliomas are managed by chemotherapy, resection 
surgery and also radiation therapy. However, the disease  remains incurable. One of the 
exclusive factors of glioma is the diffuse infiltrative nature of tumor cells into adjacent brain 
parenchymal. This has led to incomplete resection and regrowth of the cancer. Therefore, 
oncolytic virus offered promising technique of eradicating the gliomas as it well known to 
selectively infect only  the cancerous cell without harming the normal brain tissue. 
As reviewed by Biederer et al., 2002, some of the major advantages of gene therapy and 
oncolytic virus therapy includes: oncolytic viruses can be engineered by recombinant 
genetic technology to meet specific targets, pose unique pharmacokinetics properties as its 
ability to amplify its own input dose and limited side effects to normal tissue. This limited 
side effect is extended with no adverse effect concerning allergy and asthmatic. 
(Schirrmacher and Fournier, 2009) 
Oncolytic viruses are the foreign body that have innate capacity to stimulate host cytokines 
for potential anticancer activity. In this regards, some oncolytic viruses infect the target cells 
of different species and produce non-infectious virion but infected cells will express viral 
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antigens that later attract host antibody against the cancerous cells. (Sinkovics & Horvath, 
2000). Tumor cell is immunogenically poor that leads them to escape from being killed by 
the body immune system. For example, NDV can also infect freshly isolated patient-derived 
melanoma cells that further lead to increase of viral antigens at the cell surface 
(Schirrmacher et al., 1999). On the other hand, the different host origin or animal viral are 
capable of infecting human cells where the pre-existing antibody is low. 
Particularly to the reovirus, NDV virus and other simple single stranded RNA virus, their 
replications are incapable of recombination. In another words, the virus replication does not 
involve the intermediate DNA steps during their replication and thus no possibility of 
mutation insertion of viral RNA to host genome. Besides, the virus did not carry the 
oncogenes. 
However, gliomas are always reported with single cell infiltration. Surrounding normal 
tissue therefore, may inhibit the virus spread that requires cell to cell contact and limits the 
local treatment implantation.    
4. Viral genomic and infection 
On the genomic basis, every oncolytic virus is characterized with several proteins that help 
them to establish the infection to the host cell as well as the cancerous cells.   
For the ND virus, it is an avian virus with the genome consisting of 15 kilo base pairs of 
non-segmented, single-stranded RNA, coded for 6 main structural proteins. These genes 
namely nucleocapsid (NP), phosphorylation (P), matrix (M), fusion (F), hemaglutinin-
neuraminidase (HN), and RNA-dependent RNA polymerase (L) proteins  are found to be in 
3’ NP-P-M-F-HN-L 5’ arrangement. 
The NP protein is the most abundant protein found in the virion. Electron microscopic study 
reveals that the protein exists as flexible helical structure with a diameter of about 18 nm in 
length and 1 µm height. Its structure resembles classical morphology with spikes protruding 
from the central channel (Yusoff and Tan, 2001). Each NP subunits consists of 489 amino 
acids with molecular mass of about 53 kDa. In viral replication process, NP subunits in 
association of P and L proteins encapsidate the genomic RNA into RNase-resistant 
nucleocapsid. This complex, instead of naked viral RNA, becomes the RNA template for 
transcription and replication processes of the viral RNA genome. 
The polycistronic phosphoprotein (P) gene codes for protein of 395 amino acids with a 
calculated molecular weight of 42 kDa (McGinnes et al., 1988). In the viral transcriptase 
complex, P protein acts as a cofactor with dual functions; stabilizing the L protein as well as 
placing the polymerase complex (P:L) on the formed NP:RNA template for mRNA 
synthesis. Apart from the P protein which is encoded by an unedited transcript of the P 
gene, NDV was also shown to edit its P gene mRNA to produce V and W proteins. Insertion 
of one G residue at the conserved editing site (UUUUUCCC, genome sense) will produce 
the V protein, while insertion of two G residues at the same site will give W protein. The 
real functions of these two non-structural proteins are yet to be identified but some studies 
shows that V protein significantly contributes to the virus virulence (Huang Z et al., 2003). 
M gene codes for the matrix protein. It can be found between the nucleocapsid and viral 
envelope proteins. The protein which consists of 371 to 375 amino acids, is considered to be 
the central organizer of viral morphogenesis such as in making interactions with the 
cytoplasmic tails of the integral membrane proteins, the lipid bilayer, and the nucleocapsids.  
The F gene, an important determinant of NDV pathogenicity, consists of 540 to 580 amino 
acids which codes for fusion protein or known as fusion glycoprotein Type 1. Virulent and 
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avirulent NDV are characterized by the presence of multibasic and single basic residues in 
the Fo cleavage site respectively as there is a difference in the amino acid sequences 
surrounding the precursor Fo for both the virulent and avirulent strain. The amino acid 
sequences in a virulent strain renders the F protein to be susceptible to cleavage by the host 
protease and leads to a fatal systemic infection. It was reported that combination of F and 
HN proteins initiates the NDV infection (McGinnes and Morrison, 2006).  
The HN gene codes for hemaglutinin-neuraminidase protein which is the major antigenic 
determinant of all paramyxoviruses. This multifunctional protein is responsible for 
attachment to receptors containing sialic acid and neuraminidase (NA) activity. It has been 
considered that the role of the neuraminidase activity is to prevent self-aggregation of viral 
particles during budding at the plasma membrane.  In addition, HN also has a fusion-
promoting activity meaning that coexpression of HN and F is required for cell-cell fusion to 
be observed. 
RNA-dependent RNA polymerase (L) protein is the largest protein in the NDV genome. It 
consists of 2200 amino acid residues. This protein forms a complex with P protein, and both 
of these components are required for polymerase activity with NP:RNA templates. The P:L 
complex can make mRNA in vitro that is both capped at its 5’ end and contains a polyA tail 
at the 3’ end.  
Newcastle disease virus initiates infection through attachment of viral membrane to host cell 
surface receptor, the sialic acid-containing molecule which fused with the viral HN protein. 
Activated HN protein causes conformational changes to the viral F protein which brings the 
virion and the host membranes into close proximity (Morrison, 2003). This process allows 
for the viral nucleocapsid to enter the host cytoplasm. After this step, the nucleocapsid 
complex (RNA:NP:P:L) directs primary transcription of mRNAs which is complementary to 
the viral negative strand genome. These mRNA will later serve as templates for further 
negative strand RNA resulting in genome amplification. Secondary transcription then 
occurs in the same manner as the primary transcription but using the progeny 
nucleocapsids instead of the earlier parental’s. After transcription is the translation process 
which produce the viral proteins followed by nucleocapsid assembly, association of P and L 
proteins, and further encapsidation. All these processes occur in the host cytoplasm. The 
almost completed virion then moves to the plasma membrane and is released by budding 
and rendered itself with an envelope coat from the host plasma membrane.  
In the oncolytic study, the new NDV’s virion was detected as early as 3 hours post infection 
and apoptotic cell death of glioma was detected via life cell imaging in our study as early as 
7 hours post infection. The specific protein of NDV that interacts in the oncotropic 
mechanism however remains unclear but Elankumaran et al, (2007)  reported that it was 
associated with the HN protein.  
Schirrmacher and Fournier, 2009 summarised that following the intravenous injection of 
NDV, the virus was mainly detected in the lung, blood, liver and spleen at 0.5 hour. The 
amount of virus  decreased rapidly over time and reached the detection limit at less than 1 
day (blood and thymus), 2 days (kidney), and around 14 days (in lung, liver and spleen). 
5. Glioblastoma and oncolytic selective mechanism 
The molecular biology of gliomas has provided new insights in the development of brain 
tumors.  These dysregulated cell signalling pathways that have been identified  are now 
becoming the focus of a specific molecular targeted therapy (Chamberline et al., 2006). The 
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overexpression of these defective genes gives the opportunity to oncolytic virus to infect the 
gliomas. 
In the study of reovirus, the virus infection leads to activation of dsRNA-activated protein 
kinase (PKR), which phosporylates the a-subunit of eIF-2, resulting in termination in the 
initiation of translation of viral transcript in normal cells. However, PKR kinase activity is 
impaired, allowing the virus replication to proceed. Ras-mediated signal transduction is 
activated in most human cancers due to either mutated Ras or mutated epidermal growth 
factor receptor (EGFR) (Kirn et al., 2001)). In GBM, 50% was found with EGFR 
overexpression and high Ras expression especially in the primary GBM. (Aghi M. & Chiocca 
E.A., 2006)  
Oncolytic viruses are believed to replicate and and lyse different  malignant cells  in vitro 
and in vivo as a result of an impaired type I interferon response in cancer cells. In Miyakoshi 
et al study, oncogenes activation in human glioblastoma multiform had increased the 
activation of protein kinase. This leads to interferon synsthesis and the inhibition of  
tumoregenesis. (Miyakoshi et al, 1990).  In gliomas however, the anti-tumor response is 
impaired by glioma-derivative immunosuppressing factors such TGF-b, IL-10, 
prostaglandin E2 and gangliosides. TGF-b is the most prominent immunosuppresor that 
plays a major role in glioma biology whose overexpress and become the hallmark of the 
gliomas.  
On the other hand, normal brain cells response to the viral infections leads to stimulation of 
the patern-recognition-receptors (PRRs) and later activates the Type 1 interferon.( Franz et 
al., 2010). The type 1 interferon futher binds and activates the Janus kinases JAK1 and TYK2 
which inturns phophorylates the activators for transcription of STAT1 and STAT2. The 
STAT proteins later heterodimers and forms a complex with IRF9. The complex is known as 
ISGF3 that futher provides DNA recognition and simultaneously produces the interferon-
stimulated genes (IGS) that creates the antiviral state in the target cells and blocks viral 
replication. In this regards, interferon-beta is the principle antiviral factor secreted by NDV-
infected cells. Consequently, the interferon defective tumor cells gives more opportunity for 
the NDV to effectively replicate compared to normal cell and it is concluded that this 
replication-competent virus selective mechanism is associated with the defect of the host 
interferon (Krishnamurthy et al., 2006).This is summarised in the Figure 2 below. 
Recently, Puhlmann  et al has established Rac 1 as a protein which activity is critical for both 
oncolysis virus sensitivity and autonomous growth behaviour of cancer (Puhlmann et al., 
2010). Rac1 plays a role as a  pleiotropic regulator of multiple cellular functions including 
actin skeleton reorganization, gene transcription and cell migration. Rac1 is a key 
contributor to glioma cell survival, probably via multiple signaling pathways including JNK 
(Halatsch et al, 2009) but is found to be critical for the replication of oncolytic NDV to the 
highly tumorigenic ras-transformed skin carcinoma cells 
However, despite several entry-line association, there are several physicals barriers that is 
present in the gliomas microenvironment that blocks the virus distribution. The extracellular 
matrix (ECM), hypoxic region, and high interstitial pressure are amongst the major 
challenge in achieving lasting oncolytic virus infection (Franz et al., 2010) 
Besides that, GBM is currently described with multiple interactive dysregulated cell 
signalings pathway and this could lead to the inconsistency of outcome (Chamberline et al., 
2006) in bigger population target.  
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Fig. 2. 
6. Cell cycle arrest and pathway 
Glioma has been classified according to their hypothesized line of differentiation that is 
whether they display features of astrocytic, oligodendroglial or ependymal cells. These are 
graded on the scale of grade one to grade four according to the degree of malignancy judged 
by histological features. At the molecular level, the mutation that leads to different glioma 
grades presented with several relevant pathways. In the high grade astrocytoma for 
example, retinoblastoma mutation is found at approximately 25 percent. In this regard, 
retinoblastoma is a major regulator of cell cycle progression  where mutational inactivation 
of retinoblastoma leads to unschedule cell cycle entry (Maher et al., 2001).  
Cell cycle is a series of cellular events which leads to cell division and replication. Generally, 
cell cycle mechanism involves 4 different stages; G1 (gap 1), S (synthesis), G2 (gap 2) and M 
(mitosis). G1 is an interphase between the end of M (mitosis) phase and the beginning of a 
new cell cycle. At this phase, the cell either prepares to enter the S (synthesis) phase or stops 
dividing (quiescence). If the cell receives growth signal to replicate, it will move to S phase 
where it starts synthesizing nucleic acid. Once DNA replication completes, the cell will enter 
G2 phase. Here, synthesis of crucial proteins involved in cell division like microtubules 
occurs and once complete, these cells will move to the M phase and divide itself into 2 
daughter cells. All these 4 processes should occur without any disturbance from inside or 
outside of the cell. Each of the cycle phases is very critical and if anything goes wrong at any 
stage especially during G1 and M, they can cause mutations and may lead to cancer. Normal 
cell usually has several systems to check for errors at each phase and this is known as phase 
checkpoints.  
Transition from G1 to S phase is controlled mostly by cyclin-dependent kinases (Cdk2, Cdk4, 
and Cdk6) and their substrates. These Cdks regulate the retinoblastoma family proteins 
www.intechopen.com
 
Brain Tumors - Current and Emerging Therapeutic Strategies 
 
382 
(p107, p130, and pRb) by phosphorylation. Initial partial inactivation of pRb by Cdk4 and 
Cdk6 induce transcription of E-type cyclins. These cyclins activate Cdk2 which further 
phosphorylates the pRb and other substrates. The Cdks are regulated by different levels 
involving interaction with positive and negative partners. Amongst the inhibitors are the 
Cip/Kip family proteins and one of them is p27Kip1. This protein can binds to cyclin D either 
alone or when complexed to its catalytic subunit CDK4. By doing so, it inhibits catalytic 
activities (phosphorylation) of CDK4 towards pRB protein. It was reported that 
phosphorylation at the Thr187 of p27KIP1 by Cyclin E/CDK2 complex promotes its 
degradation by recognition of this phosphorylated p27KIP1 by SCF(Skp2) which has the E3 
ubiquitin ligase activity (Ungermannova et al., 2005). Degradation of p27KIP1 starts the 
generation of cyclin A-dependent kinase activity which will push the cells from G phase to S 
phase in the cell cycle. In several studies done in viral infections which induces cell cycle 
arrest, it was found that the level of this inhibitor protein increases significantly after 
infection, which leads to arrest of the cell replication process. 
A successful introduction of viral genome into a host cell usually causes chaos in the host 
system and ends-up with the production of viral genome instead of host. Studies done on 
certain viruses revealed that these viruses are able to stop the host cellular replication 
mechanism namely cell cycle arrest which may render the virus with advantages in taking 
over the whole machinery system. This cell arrest is usually associated with elevation or 
suppression of players in the cell cycle from members of cyclins, CDKs, and inhibitors. For 
instance, infection of influenza A virus A/WSN/33 (H1N1) causes changes in the host 
protein expression level of cyclin E and cyclin D1, as well as p21 which are amongst the key 
molecules of cell cycle (He et. al., 2010). Besides that, p27 is one of the protein involve in the 
retinoblastoma pathway where glioma cell lines exhibit an inverse corelation between the 
level of p27 protein and proliferation index (Maher et al., 2001) that could be investigated as 
a rational component target in cell cycle arrest.  
Many other viruses were also reported to cause cell cycle arrest upon infection such as 
measles virus, human immunodeficiency virus-type 1 (HIV-1), and herpesvirus. Our recent 
findings on NDV infection also reveal the potential of this virus to block cell cycle in tumor 
cells.  
7. Methods 
7.1 Virus propagation 
Avirulent NDV propagation is carried out in the Class II laboratory (Laboratory Biosafety 
Level). Generally, the egg shell is cleaned with 70% ethanol and then candling is done  to 
ensure that the embryo is still alive. Then a mark is made slightly above the air-sac where 
the mark is pricked with a 21G needle. Through this tiny hole dilution of NDV in PBS is 
introduced into the allantoic fluid cavity. The hole is then sealed with melting wax and the 
egg is incubated at 37oC for 48 to 72 hours (subjected to viral virulence) to allow for the viral 
propagation as well as the embryo growth. 
Prior to allantoic fluid collection, the embryo is killed by placing it at 4oC for about 5 hours. 
Besides killing the embryo, this cold temperature also shrinks the blood capillary inside the 
egg, thus, extracting the allantoic fluid would be easier. Allantoic fluid is then collected and 
clarified at 8,000 x g for 30 minutes to remove the debris such as red blood cells and yolk if 
any. Further centrifugation at 20,000 x g for 2 and half hours will precipitate the virus at the 
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bottom of the centrifuge tube. The pellet is then re-suspended in NTE or PBS buffer 
according to further work specifications.  
Virus obtained at this stage can be used in work like HA, HI and other several tests but not 
for infection and other works that need pure virus application. Virus purification is achieved 
by separating the virus from other tiny contaminants in the viral suspension through 
glucose gradient. Special ultracentrifuge with vacuum function is needed for this process 
since the virus will be spinning at 38,000 x g for 4 hours to get better separation. Band 
containing virus is then identified and extracted for further centrifugation at the same speed 
in 2 hours. This will pellet the virus at the bottom of the tube. Pure virus pellet is now re-
suspended in NTE or PBS buffer and kept at -20oC or -80oC for longer storage.  
7.2 In vitro cytotoxic study 
Cell lines were cultured in the media and supplemented according to supplier 
recommendations. For the cytotoxicity study, adapted from the method by Zulkifli et al., 
2009, the normal and glioma cell lines were seeded at 1 x 105 in 96-well plate and incubated 
overnight in 37°celcius incubator supplemented with 5% CO2 gas. Following the attachment 
of the cells next day, the media was changed. The cells later treated with virus at MOI of 
log10 serial concentrations and incubated for 24, 48 and 72 hours. Relative cell viability later 
tested with 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium (MTS) reagent. The absorbance values were expressed as a percentage and the 
sigmoidal dose response curve were plotted versus virus dose. The EC50 achieved by the 
curve represents the dose of virus that reduces the maximal light absorbance capacity of an 
exposed cell culture by 50% and is proportional to the percentage of cells killed by the virus. 
 
 
Fig. 3. Confluence glioma cell line in cell culture 
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Fig. 4. Apoptotic glioma cells after 48 hours infection with newcastle disease virus 
7.3 Protein analysis by SDS-PAGE 
Cell cycle process occurs by interactions of many protein players. These proteins are 
produced at specific rate and amount to meet the purpose; overexpression or reduction in 
the amount suggests for disturbance or changes in the cycle process, perhaps causing cell 
cycle arrest. There are several options that can be carried out in a laboratory in order to find 
out on this changes of protein expression level, but the established method are the SDS-
PAGE and Western blot. These two methods allow researchers to find the difference of 
specific protein level between different samples qualitatively and even quantitatively.   
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) is a technique to 
separate different proteins based on their size by running proteins through a gel forced by 
electrical voltage. SDS-PAGE gel consists of two parts; the bottom part namely the resolving 
gel and the upper part which is the stacking gel. Different percentage of resolving and 
stacking gels can be prepared depending on the size of protein of interest but the standard 
percentage in most practice is 12% resolving gel and 5% stacking gel. A 12 % resolving gel 
was prepared first by mixing 30% acrylamide solution, 1.5M Tris (pH 8.8), 10% (w/v) SDS in 
distilled water, 10% (w/v) ammonium persulfate (APS) in distilled water, deionized water 
(dH2O) and N,N,N’,N’-Tetramethylethylenediamine (TEMED) in a clean beaker and 
immediately poured into a set of SDS-PAGE gel casting apparatus (Bio-Rad, USA) to an 
appropriate level. Immediately after this step, appropriate amount of n-butanol was layered 
onto the gel and it was left for 45 minutes at room temperature to solidify. After butanol 
layer was removed and rinsed with dH2O, stacking gel was prepared by mixing 30% 
Acrylamide solution, 0.5M Tris (pH 6.8), 10% (w/v) SDS in distilled water, 10% (w/v) APS 
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in distilled water, dH2O, and TEMED in a clean beaker. This mixture was then mixed 
properly and immediately layered on top of the resolving gel. A comb was inserted into the 
stacking gel and everything was allowed to set for about 45 minutes. Then the comb was 
removed carefully and the glass plates holding the gel was transferred into an inner 
chamber of Mini Protean-3 Cell electrophoresis tank (BioRad, USA). About 400 ml SDS-
PAGE running buffer consisting of  0.025 M Tris, 0.192 M glycine, and 0.1% (w/v) SDS in 
distilled water (pH 8.3) was prepared and poured into the inner chamber until full while the 
rest was emptied into the electrophoresis tank.  
Samples were then prepared by mixing the cell lysate with 2X sample buffer [125 mMTris-
HCl (pH 6.8), 4% SDS, 20% glycerol, 0.0.2% Bromophenol blue, 10% 2-mercaptoethanol 
(added fresh before use)] at the ratio 1:1 and the mixture was boiled for 5 minutes. After 
that, the mixture was loaded into SDS-PAGE gel and electrophoresed at 180V for 50 
minutes. 
7.4 Western blotting and chemiluminescence 
Separated proteins in SDS-PAGE gel was then transferred using Western blotting. Briefly, 
the gel was removed carefully and layered onto a polyvinylidene fluoride (PVDF) placed at 
the middle of 4 filtered paper. Protein in the gel was transferred by electrical charges 
attraction at 100V for 1h in a protein wet transfer tank filled with Towbin’s transfer buffer 
[25 mMTris, 190 mM glycine (pH 8.0), 20% (v/v) methanol]. After that, blocking step was 
carried out by soaking the PVDF in 5% milk diluents for 1h at room temperature or 
overnight at 4oC. The membrane was washed in TBST buffer [50 mMTris-HCl, 150 
mMNaCl, 0.01 Tween 20] 3 times (5 minutes each time) to remove the blocking reagent. 
Specific protein detection was achieved by incubating the membrane in primary antibody 
for 1h at room temperature. The membrane was then washed with TBST buffer 3 times (5 
minutes each) before it was incubated in secondary antibody conjugated with horseradish 
peroxidase (HRP) for another 1 h at room temperature. After that, the membrane was 
washed again with TBST for 3 times (5 minutes each wash). 
Protein band of interest was obtained by chemiluminescence method. Reagents from 
Supersignal West Pico Chemiluminescent Substrate or Supersignal West Dura 
Chemiluminescent Substrate (Pierce, Thermo Scientific, USA) kit were added onto the 
membrane for 5 minutes incubation period, allowing for the HRP from the secondary 
antibody to bind to the substrate and fluoresce.  This signal was then captured onto a film in 
an autoradiography cassette (Fisher Scientific, PA) and developed by a film developer 
machine (AFP Imaging Corp, USA). These bands can be compared quantitatively using 
software like Image J. Data used for the purpose of  comparison helps in  identifying the 
changes in protein expression level and further other changes or disturbance in the pathway 
involved. 
7.5 Development of glioma model in mouse  
Growing the glioma model is one of the critical issue in brain tumor therapy study. One of 
the common model is the xenograft implant of glioma cell line into the immunosuppresive 
mouse. Some of the advantages of the implant model are the predictable growth rate of the 
tumor and it is reproducible in term of location besides the precise histology features. The 
implant model however fails to give the characteristic of single cell infiltration.  
The glioma model in the nude mouse were done according to Zulkifli et al. In brief, actively 
growing glioma cell lines such as DBTRG.05MG and U-87MG were harvested from culture 
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flask, counted at 1 x 107 in the PBS and subcutaneously injected to a flank of female 6-weeks 
old homozygous nu/nu Balb/c mice. Tumors grows until they were clearly growing and 
palpable measuring (by digital caliper) at 20mm3 were obtained. Tumor size is measured 
using the ellipsoid formula (Length x Width x Height x 0.5) (Tanaka et al.) twice weekly .All 
animal were kill when they lost 25% of their body weight or had difficulty in ambulating, 
feeding or grooming. The experiments must be conducted according to guidelines and 
approval by respective animal ethic committee. 
 
 
Fig. 5. The glioma growth on the nude mouse flank. 
8. Conclusion 
The oncolytic virus therapy is now amongst the fastest growing study compare to other 
salvage therapy as the current progress giving great potential in treating various cancer.  
Specific relationship of virus with tumors however shows wide variable thus multiple 
dosages and optimum temperature have to be specifically studied. Besides that, current 
outcomes of oncolytic viruses studies show the direction of specific virus to be used for the 
specific cancers. 
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